As of June 21, 2025, Medigene AG's estimated intrinsic value ranges from $2.59 to $2.59 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|---|---|
Earnings Power Value | $2.59 | +1841.0% |
Is Medigene AG (MDG1.DE) undervalued or overvalued?
With the current market price at $0.13, the stock appears to be significantly undervalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Medigene AG's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 2.8% | 3.3% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.24 | 0.47 |
Cost of equity | 5.0% | 7.7% |
Cost of debt | 6.8% | 7.0% |
Tax rate | 2.2% | 2.7% |
Debt/Equity ratio | 1.07 | 1.07 |
After-tax WACC | 5.9% | 7.2% |
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
EPV Component | Value |
---|---|
Normalized Earnings | $3M |
Discount Rate (WACC) | 7.2% - 5.9% |
Enterprise Value | $38M - $46M |
Net Debt | $(11)M |
Equity Value | $49M - $58M |
Outstanding Shares | 21M |
Fair Value | $2 - $3 |
Selected Fair Value | $2.59 |
Metric | Value |
---|---|
Market Capitalization | $3M |
Enterprise Value | $-9M |
Trailing P/E | 0.00 |
Forward P/E | 0.00 |
Trailing EV/EBITDA | 4.45 |
Current Dividend Yield | 0.00% |
Dividend Growth Rate (5Y) | 0.00% |
Debt-to-Equity Ratio | 1.07 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Earnings Power Value | 100% | $0.26 |
Weighted Average | 100% | $2.59 |
Based on our comprehensive valuation analysis, Medigene AG's weighted average intrinsic value is $2.59, which is approximately 1841.0% above the current market price of $0.13.
Key investment considerations:
Given these factors, we believe Medigene AG is currently significantly undervalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.